Table of Contents
ISRN Neurology
Volume 2013 (2013), Article ID 496079, 12 pages
http://dx.doi.org/10.1155/2013/496079
Research Article

Study on the Dynamic Changes in Synaptic Vesicle-Associated Protein and Axonal Transport Protein Combined with LPS Neuroinflammation Model

State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received 27 June 2013; Accepted 14 August 2013

Academic Editors: A. Arboix and C.-Y. Hsu

Copyright © 2013 Rui Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. W. Langston, “Parkinson's disease: current and future challenges,” NeuroToxicology, vol. 23, no. 4-5, pp. 443–450, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. C. W. Olanow and W. G. Tatton, “Etiology and pathogenesis of Parkinson's disease,” Annual Review of Neuroscience, vol. 22, pp. 123–144, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Dutta, P. Zhang, and B. Liu, “The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery,” Fundamental and Clinical Pharmacology, vol. 22, no. 5, pp. 453–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Klein and M. G. Schlossmacher, “Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder,” Neurology, vol. 69, no. 22, pp. 2093–2104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Papapetropoulos, N. Adi, J. Ellul, A. A. Argyriou, and E. Chroni, “A prospective study of familial versus sporadic Parkinson's disease,” Neurodegenerative Diseases, vol. 4, no. 6, pp. 424–427, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Liu, “Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease,” AAPS Journal, vol. 8, no. 3, pp. E606–E621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Wyss-Coray and L. Mucke, “Inflammation in neurodegenerative disease: a double-edged sword,” Neuron, vol. 35, no. 3, pp. 419–432, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. W. J. Streit, J. R. Conde, S. E. Fendrick, B. E. Flanary, and C. L. Mariani, “Role of microglia in the central nervous system's immune response,” Neurological Research, vol. 27, no. 7, pp. 685–691, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Gao, J. Jiang, B. Wilson, W. Zhang, J. Hong, and B. Liu, “Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease,” Journal of Neurochemistry, vol. 81, no. 6, pp. 1285–1297, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Liu and J. Hong, “Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. C. F. Orr, D. B. Rowe, and G. M. Halliday, “An inflammatory review of Parkinson's disease,” Progress in Neurobiology, vol. 68, no. 5, pp. 325–340, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Zhou, X. Liu, D. Niu, F. Li, Q. He, and X. Wang, “Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection,” Neurobiology of Disease, vol. 18, no. 3, pp. 441–449, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Hunter, B. Cheng, D. Choi et al., “Intrastriatal lipopolysaccharide injection induces Parkinsonism in C57/B6 mice,” Journal of Neuroscience Research, vol. 87, no. 8, pp. 1913–1921, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Ikenaka, M. Katsuno, K. Kawai, S. Ishigaki, F. Tanaka, and G. Sobue, “Disruption of axonal transport in motor neuron diseases,” International Journal of Molecular Sciences, vol. 13, no. 1, pp. 1225–1238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Blackstone, C. J. O'Kane, and E. Reid, “Hereditary spastic paraplegias: membrane traffic and the motor pathway,” Nature Reviews Neuroscience, vol. 12, no. 1, pp. 31–42, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Chen and D. C. Chan, “Mitochondrial dynamics—fusion, fission, movement, and mitophagy—in neurodegenerative diseases,” Human Molecular Genetics, vol. 18, no. 2, pp. R169–R176, 2009. View at Google Scholar · View at Scopus
  17. C. Crimella, C. Baschirotto, A. Arnoldi et al., “Mutations in the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in axonal Charcot-Marie-Tooth type 2,” Clinical Genetics, vol. 82, no. 2, pp. 157–164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. K. J. De Vos, A. J. Grierson, S. Ackerley, and C. C. J. Miller, “Role of axonal transport in neurodegenerative diseases,” Annual Review of Neuroscience, vol. 31, pp. 151–173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. S. Kim-Han, J. A. Antenor-Dorsey, and K. L. O'Malley, “The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons,” The Journal of Neuroscience, vol. 31, no. 19, pp. 7212–7221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. P. S. Whitton, “Inflammation as a causative factor in the aetiology of Parkinson's disease,” British Journal of Pharmacology, vol. 150, no. 8, pp. 963–976, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Bardehle, M. Kroger, F. Buggenthin et al., “Live imaging of astrocyte responses to acute injury reveals selective juxtavascular proliferation,” Nature Neuroscience, vol. 31, pp. 1–9, 2013. View at Google Scholar
  22. P. Zhang, K. M. Lokuta, D. E. Turner, and B. Liu, “Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia,” Journal of Neurochemistry, vol. 112, no. 2, pp. 434–443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Chevalier-Larsen and E. L. F. Holzbaur, “Axonal transport and neurodegenerative disease,” Biochimica et Biophysica Acta, vol. 1762, no. 11-12, pp. 1094–1108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Y. Goldstein, X. Wang, and T. L. Schwarz, “Axonal transport and the delivery of pre-synaptic components,” Current Opinion in Neurobiology, vol. 18, no. 5, pp. 495–503, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Millecamps and J. P. Julien, “Axonal transport deficits and neurodegenerative diseases,” Nature Reviews Neuroscience, vol. 14, no. 3, pp. 161–176, 2013. View at Google Scholar
  26. S. J. King and T. A. Schroer, “Dynactin increases the processivity of the cytoplasmic dynein motor,” Nature Cell Biology, vol. 2, no. 1, pp. 20–24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. C. M. Waterman-Storer, S. B. Karki, S. A. Kuznetsov et al., “The interaction between cytoplasmic dynein and dynactin is required for fast axonal transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 22, pp. 12180–12185, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. B. H. LaMonte, K. E. Wallace, B. A. Holloway et al., “Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration,” Neuron, vol. 34, no. 5, pp. 715–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Hafezparast, R. Klocke, C. Ruhrberg et al., “Mutations in dynein link motor neuron degeneration to defects in retrograde transport,” Science, vol. 300, no. 5620, pp. 808–812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Salinas, L. G. Bilsland, and G. Schiavo, “Molecular landmarks along the axonal route: axonal transport in health and disease,” Current Opinion in Cell Biology, vol. 20, no. 4, pp. 445–453, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. G. J. Augustine and M. E. Burns, “Proteins involved in synaptic vesicle trafficking,” Journal of Physiology, vol. 520, no. 1, pp. 33–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Bonanomi, F. Benfenati, and F. Valtorta, “Protein sorting in the synaptic vesicle life cycle,” Progress in Neurobiology, vol. 80, no. 4, pp. 177–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. T. C. Südhof, “The synaptic vesicle cycle,” Annual Review of Neuroscience, vol. 27, pp. 509–547, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Perlson, S. Maday, M. Fu, A. J. Moughamian, and E. L. F. Holzbaur, “Retrograde axonal transport: pathways to cell death?” Trends in Neurosciences, vol. 33, no. 7, pp. 335–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. K. E. Cosker, S. L. Courchesne, and R. A. Segal, “Action in the axon: generation and transport of signaling endosomes,” Current Opinion in Neurobiology, vol. 18, no. 3, pp. 270–275, 2008. View at Publisher · View at Google Scholar · View at Scopus